1 in 18 Black Market Peptide Vials Matched Its Label
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
An Australian lab tested 18 vials sold as retatrutide this year. Exactly one contained what the label claimed. Roughly a third read about 30% high, roughly a third about 30% low, and one contained none of the peptide at all. The surprise for the researchers was the overdosing, because the assumption in this market has always been that you're being shortchanged rather than overdosed.
The catch is the unpredictability of the dose, not the strength
The testing was done by Leeder Analytical, a commercial lab in Melbourne, and reported by the ABC (ABC News). A separate three-vial batch obtained from users was arranged by researchers at the University of Queensland's School of Public Health with the harm reduction group PED Test Australia. In that batch one vial was below label and two were at much higher concentration.
Analytical chemist Grace Hamann said the direction caught her out: "the fact that we've had almost equal amount to be over 100 per cent than under 100 per cent, surprises me." She also noted how fast this has grown, saying about half her job is now peptide testing and that daily requests started arriving around October 2025.
Dr Tim Piatkowski, the UQ researcher, put it against his own baseline: "When we tested a number of steroids, we saw underdosing to be hugely prevalent with a very low percentage of overdosed substances. I definitely didn't expect that level of overdosing." His group reported the findings to the journal Drug and Alcohol Review.
Why that matters more than it sounds: someone who assumes their vial is weak, and quietly doubles up to compensate, is running the exact scenario that turns a labelling problem into an overdose. Inconsistent dosing from one vial to the next risks those injecting peptides to overdose without changing anything on their end.
A purity test is not a safety test
The sharpest consumer point comes from a liver transplant specialist.
Dr Marie Sinclair, who has treated patients in Victoria for liver failure after taking black market products labelled as retatrutide, said of the testing sellers commission: "All that they know from this testing is that there is some retatrutide in their vials. It doesn't actually tell them if there's any other contaminants or any other drugs or medications that could be mixed with them." On her own cases she added that two laboratories ran extensive analysis and "even with extensive testing we don't have the full picture."
Hamann made a related point from the other side of the counter: "Our results don't give the validation sellers are after." She has said that in her testing experience the peptide typically makes up only around 10% of what is in a vial, leaving the rest unaccounted for. That's her general impression rather than a measured contaminant finding, so we won't present it as a solid truth, but you should consider what else is in the vial outside of what the results say.
Australia's Therapeutic Goods Administration is on the record too. Chief Medical Advisor Professor Robyn Langham described these as counterfeit products and said they "have not been tested in clinical trials, they have not been tested in terms of their manufacturing, and they've not been tested for their safety, and people are injecting these into their body." The ABC reports TGA figures of more than 94,500 unapproved peptide products destroyed this year alongside the Australian Border Force.
US testing found the same market failing in the opposite direction
A peer-reviewed study published in 2024 bought gray market semaglutide advertised as at least 99% pure. Measured purity came in between 7.70% and 14.37%, and endotoxin was present in all three samples (Journal of Medical Internet Research).
So one continent finds product grossly under-potent and contaminated, another finds it swinging both ways. The consistent finding across both is that the number on the label doesn't carry the actual contents of the vial. Our piece on tanning peptides and what the FDA has published covers a third corner of the same market.
Where peptide regulation actually stands, briefly
We've covered this in depth before, so this is the short version, current as of August 26th, 2026.
- Retatrutide is not approved anywhere. It remains in Phase 3, and Lilly has said it plans to submit for approval in the first quarter of 2027 (Lilly).
- Retatrutide cannot lawfully be compounded either. The FDA states that "retatrutide and cagrilintide cannot be used in compounding under federal law," and that neither is a component of an approved drug (FDA).
- The July advisory committee went against FDA staff. At the July 23 and 24, 2026 Pharmacy Compounding Advisory Committee meeting on seven peptides, FDA scientific reviewers recommended against adding any of them for the uses evaluated. The committee then voted to recommend adding six of the seven, BPC-157, KPV, TB-500, MOTS-c, epitalon and semax, rejecting only emideltide (FDA meeting page)(as analysed by Mintz).
- Nothing about that changed the law. Committee recommendations are non-binding, the FDA has posted no minutes or formal tally, no Federal Register action has followed, and none of these peptides can lawfully be compounded today.
- The border is tightening. The FDA detains foreign GLP-1 active ingredients by default unless the supplier is on a Green List, having found 21% of 48 evaluated sites noncompliant (Import Alert 66-80).
What "research use only" actually means
That label is doing less work than buyers think. The provision sits at 21 CFR 809.10(c)(2)(i), inside the medical device subchapter governing in vitro diagnostic products (Code of Federal Regulations). It's a narrow labelling exemption for laboratory test reagents in the research phase. Basically, it’s a label for ingredients never intended to be injected into a human body.
An injectable peptide isn't an in vitro diagnostic. The required wording even includes "not for use in diagnostic procedures," so the sticker narrows a product's lawful use rather than widening it. The FDA has separately warned companies selling semaglutide, tirzepatide and retatrutide falsely labelled for research purposes while shipping to consumers with dosing instructions.
Final Takeaway
Seventeen of 18 vials tested were not what they said they were, in both directions. If you can't trust the concentration, you can't calculate a dose, and a certificate of analysis doesn't fix that, because purity says nothing about what else is in the vial, only that the ingredient you want is present.
If you're weighing a gray market source against a licensed one on price, our guides to 503A and 503B pharmacies and checking a pharmacy's licence in your state show what the regulated chain actually looks like.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
Some peptides are FDA-approved medicines and some "research" peptides are risky. A plain-language guide to telling safe sources from unsafe ones.
An FDA panel backed 6 of 7 peptides for the compounding list. See the votes, what each was proposed to treat, and what has to happen next.
Melanotan II is sold as a tanning shortcut. See the FDA's own safety language, the published case reports, and where the 2026 peptide review stands.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner where she works on marketing, content creation, and operations. She has over 10 years experience in the content creation space, including in the GLP-1 space where she works to stay on top of access news, research updates, and lifestyle tips guided by science.